Effect of targeting CYP3A5 in glioma treatment
By identifying and utilizing CYP3A5 biomarkers and combining the combined treatment of Cobicistat and temozolomide, the difficulties in predicting the drug resistance and prognosis of glioblastoma treatment have been solved, and effective diagnosis and treatment of glioblastoma have been achieved, which has enhanced the effectiveness of glioblastoma. Sensitivity of chemotherapy drugs.
Patent Information
- Application Number
- CN202411200948.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-08-29
AI Technical Summary
The therapeutic resistance and prognosis prediction of glioblastoma have not been fully explained, and it is difficult for the prior art to effectively utilize the role of targeting CYP3A5 in glioblastoma.
CYP3A5 is provided as a biomarker for the diagnosis, prognosis, prevention and treatment of glioblastoma by detecting its expression level and designing inhibitors such as Cobicistat combined with temozolomide to enhance therapeutic effects.
The high expression level of CYP3A5 in glioblastoma is related to disease progression. The sensitivity of glioma to chemotherapy drugs can be enhanced by targeting CYP3A5 inhibitors, improve patient prognosis, and provide potential therapeutic targets and diagnostic tools.
Smart Images

Figure CN119061140A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine and relates to the role of targeting CYP3A5 in the treatment of glioma. Background Art
[0002] Glioblastoma (GBM) is the most common and lethal malignant brain tumor. Even with the implementation of standard treatments including surgery, radiotherapy, and chemotherapy, the current median overall survival of newly diagnosed GBM is still short, at 15-17 months. Glioblastoma stem cells (GSCs) promote tumor phenotypic plasticity and heterogeneity and are responsible for tumor initiation, progression, and therapeutic resistance. GSCs maintain self-renewal through molecular signaling pathways such as Notch and receptor tyrosine kinases, which are growth factor receptors that activate PI3K-AKT or STAT signaling cascades. Temozolomide (TMZ) treatment generates evolutionary selection pressure, leading to the proliferation of resistant GSCs, which are characterized by enhanced DNA repair capacity. However, the mechanisms by which GSCs maintain self-renewal and promote chemoresistance remain poorly elucidated.
[0003] CYP3A5 is a member of the cytochrome P450 (CYP) enzyme superfamily and is involved in drug metabolism and lipid synthesis. P450 acts as a monooxygenase, utilizing reduced NAD (NADH) or reduced nicotinamide adenine dinucleotide phosphate (NADPH) as an electron donor (NAD(P)H+O2+R→NAD(P)++RO+H2O). The role of CYP3A5 in tumors is background. CYP3A5 has been reported to play a tumor suppressor role in hepatocellular carcinoma via the mTORC2 / Akt signaling pathway. On the other hand, CYP3A5 is thought to mediate therapeutic resistance in pancreatic ductal adenocarcinoma. Nevertheless, the role of CYP3A5 in GBM progression is unclear. Summary of the invention
[0004] In order to make up for the deficiencies of the prior art, the object of the present invention is to provide a biomarker CYP3A5 associated with glioblastoma, which can be used for the diagnosis, prognosis, prevention and / or treatment of glioblastoma.
[0005] In order to achieve the above object, the present invention adopts the following technical solution:
[0006] The first aspect of the present invention provides a glioblastoma-related biomarker.
[0007] Furthermore, the biomarker is CYP3A5.
[0008] Furthermore, the biomarker can be used for the diagnosis, prognosis, prevention and / or treatment of glioblastoma.
[0009] Furthermore, the expression level of the biomarker CYP3A5 is significantly increased in glioblastoma.
[0010] In the present invention, the term "biomarker" refers to a biological molecule present in an individual at different concentrations that can be used to predict the cancer status of the individual. Biomarkers may include, but are not limited to, nucleic acids, proteins, and variants and fragments thereof. A biomarker may be a DNA comprising all or part of a nucleic acid sequence encoding the biomarker or a complement of such a sequence. Biomarker nucleic acids useful in the present invention are considered to include DNA and RNA comprising all or part of any nucleic acid sequence of interest.
[0011] In a specific embodiment of the present invention, the biomarker includes a gene and its encoded protein and its homologs, mutations, and isoforms. The term encompasses full-length, unprocessed biomarkers, as well as any form of biomarkers derived from processing in cells. The term encompasses naturally occurring variants of biomarkers (e.g., splice variants or allelic variants).
[0012] A second aspect of the present invention provides a product for early diagnosis or prediction of the prognosis of glioblastoma.
[0013] Furthermore, the product includes a reagent for detecting the expression level of the biomarker CYP3A5 described in the first aspect of the present invention.
[0014] Furthermore, the products include chips, test kits, test strips, and high-throughput sequencing platforms.
[0015] Furthermore, the reagent for detecting the expression level of the biomarker CYP3A5 in the sample includes a reagent for detecting the expression level of the biomarker CYP3A5 mRNA in the sample, and / or a reagent for detecting the expression level of the protein and / or polypeptide encoded by the biomarker CYP3A5 in the sample.
[0016] Furthermore, the reagent for detecting the expression level of the biomarker CYP3A5 mRNA in the sample includes a probe that specifically recognizes the biomarker CYP3A5, and / or a primer that specifically amplifies the biomarker CYP3A5.
[0017] Furthermore, the reagent for detecting the expression level of the protein and / or polypeptide encoded by the biomarker CYP3A5 in the sample includes an antibody, and / or an antibody fragment, and / or an affinity protein that specifically binds to the biomarker CYP3A5.
[0018] In the present invention, the chip includes a gene chip and / or a protein chip, wherein the gene chip includes: a solid phase carrier; and oligonucleotide probes fixed in an orderly manner on the solid phase carrier, wherein the oligonucleotide probes specifically correspond to part or all of the sequence shown in CYP3A5; the protein chip includes: a solid phase carrier; and antibodies or ligands fixed in an orderly manner on the solid phase carrier, wherein the antibodies or ligands can specifically bind to the CYP3A5 protein.
[0019] Specifically, suitable probes can be designed based on the genes described in the present invention and fixed on a solid phase carrier to form an "oligonucleotide array". The "oligonucleotide array" refers to an array with addressable positions (i.e., positions characterized by distinctive, accessible addresses), each of which contains a characteristic oligonucleotide connected thereto. The oligonucleotide array can be divided into multiple subarrays as needed.
[0020] "Probe" is intended to include a nucleic acid oligomer or aptamer that specifically hybridizes to a target sequence in a nucleic acid or its complement under conditions that promote hybridization, thereby allowing detection of the target sequence or its amplified nucleic acid. Detection can be direct (i.e., produced by a probe that hybridizes directly to the target or amplified sequence) or indirect (i.e., produced by a probe that hybridizes to an intermediate molecular structure that connects the probe and the target or amplified sequence). The "target" of a probe generally refers to a sequence in an amplified nucleic acid sequence that specifically hybridizes to at least a portion of the probe sequence through standard hydrogen bonding or "base pairing". The probe may be labeled or unlabeled. The probe may be produced by molecular cloning of a specific DNA sequence or may be synthesized. A person skilled in the art to which the present invention pertains can readily determine a variety of primers and probes that can be designed and used in the context of the present invention.
[0021] In the present invention, the kit can be used to detect the expression of CYP3A5 gene or protein. Preferably, the preparation or kit also contains a marker for labeling RNA samples, and a substrate corresponding to the marker. In addition, the kit may also include various reagents required for RNA extraction, PCR, hybridization, color development, etc., including but not limited to: extraction solution, amplification solution, hybridization solution, enzyme, control solution, color development solution, washing solution, etc. In addition, the kit also includes instructions for use and / or chip image analysis software.
[0022] The components of the test kit can be packaged in the form of an aqueous medium or in a lyophilized form. Suitable containers in the test kit usually include at least a vial, test tube, flask, PET bottle, syringe or other container, in which a component can be placed, and preferably, can be appropriately divided. When there is more than one component in the test kit, the test kit will usually also include a second, third or other additional container, in which additional components are placed separately. However, components of different combinations can be contained in a vial. The test kit of the present invention will also usually include a container for accommodating reactants, sealed for commercial sale. Such a container may include a plastic container of injection molding or blow molding, in which the required vial can be retained.
[0023] In the present invention, the term "sample" is used in its broadest sense. It is intended to include any tissue or material derived from a living or dead person, which may include the markers of the present invention. In a specific embodiment of the present invention, the sample may be a tumor or glioma tissue.
[0024] The third aspect of the present invention provides a pharmaceutical composition for treating glioblastoma.
[0025] Furthermore, the pharmaceutical composition comprises an inhibitor targeting the biomarker CYP3A5 described in the first aspect of the present invention.
[0026] Furthermore, the inhibitor refers to any substance that can reduce the expression of nucleic acid encoding CYP3A5, reduce the level of CYP3A5 protein, or inhibit the activity of CYP3A5, preferably a substance that reduces the activity of CYP3A5 protein, reduces the stability of CYP3A5 gene or protein, downregulates the expression of CYP3A5, reduces the effective action time of CYP3A5 protein, or inhibits the transcription and translation of CYP3A5.
[0027] Preferably, the inhibitor comprises Cobicistat.
[0028] Preferably, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier and / or excipient.
[0029] Preferably, the pharmaceutical composition is temozolomide (TMZ) and cobicistat.
[0030] More preferably, the ratio of Cobicistat to TMZ is 2:1.
[0031] In the present invention, the inhibitor includes but is not limited to: nucleic acid inhibitors, protein inhibitors, proteolytic enzymes, protein binding molecules; and combinations thereof. The nucleic acid inhibitor is selected from: interfering molecules that target CYP3A5 or its transcripts and can inhibit CYP3A5 gene expression or gene transcription, including: shRNA (small hairpin RNA), small interfering RNA (siRNA), dsRNA, microRNA, or constructs that can express or form the shRNA, small interfering RNA, dsRNA, microRNA. The protein binding molecule is selected from: substances that specifically bind to CYP3A5 protein, such as antibodies or ligands that can inhibit the activity of CYP3A5 protein; competitors for CYP3A5 ligand binding sites, including CYP3A5 receptors and their ligand binding fragments, soluble truncated CYP3A5 receptors, soluble CYP3A5 receptor fusion proteins, such as CYP3A5 fusion proteins containing the Fc part of IgG immunoglobulins, ligand fusion proteins; peptidomimetics; peptide inhibitors; small molecule compounds; and combinations thereof.
[0032] In the present invention, the "pharmaceutically acceptable carrier" refers to a carrier used for the administration of therapeutic agents, including various excipients and diluents. The term refers to pharmaceutical carriers that are not necessary active ingredients themselves and are not overly toxic after administration. Suitable carriers are well known to those of ordinary skill in the art. The pharmaceutically acceptable carrier in the composition may contain a liquid, such as water, saline, or a buffer. In addition, auxiliary substances may also be present in these carriers, such as fillers, lubricants, glidants, wetting agents or emulsifiers, pH buffer substances, etc. The carrier may also contain a cell (host cell) transfection reagent.
[0033] The present invention can use a variety of methods well known in the art to administer the inhibitor or its encoding gene, or its pharmaceutical composition to a mammal, including but not limited to oral administration, subcutaneous injection, intramuscular injection, transdermal administration, local administration, implantation, sustained release administration, etc. Preferably, the administration method is oral administration.
[0034] Preferably, gene therapy can be used. For example, the CYP3A5 inhibitor can be directly administered to the subject by methods such as injection; or, the expression unit (such as expression vector or virus, or siRNA or shRNA) carrying the CYP3A5 inhibitor can be delivered to the target site through a certain route, and the target site can express the active CYP3A5 inhibitor. The specific situation depends on the type of the inhibitor, which is well known to those skilled in the art.
[0035] The pharmaceutical composition of the present invention can also be used in combination with other drugs for treating glioblastoma. Other therapeutic compounds can be administered simultaneously with the main active ingredient, or even administered simultaneously in the same composition.
[0036] The pharmaceutical composition of the present invention can also be administered separately to other therapeutic compounds in a separate composition or in a dosage form different from the main active ingredient. Partial doses of the main ingredient can be administered simultaneously with other therapeutic compounds, while other doses can be administered separately. During the course of treatment, the dosage of the pharmaceutical composition of the present invention can be adjusted according to the severity of the symptoms, the frequency of recurrence and the physiological response of the treatment regimen.
[0037] A fourth aspect of the present invention provides an application.
[0038] Further, the application includes any of the following:
[0039] 1) Use of a reagent for detecting the expression level of the biomarker CYP3A5 described in the first aspect of the present invention in a sample in the preparation of a product for early diagnosis or prognosis of glioblastoma;
[0040] 2) Use of the pharmaceutical composition according to the third aspect of the present invention in the preparation of a product for preventing and / or treating glioblastoma;
[0041] 3) Use of a reagent for detecting the expression level of the biomarker CYP3A5 described in the first aspect of the present invention in a sample in the preparation of a product for evaluating and / or predicting the sensitivity of glioblastoma patients to TMZ, preferably, in non-responsive glioblastoma patients receiving TMZ treatment, the CYP3A5 expression level is significantly higher than that in responsive patients receiving TMZ treatment;
[0042] 4) Use of an inhibitor targeting the biomarker CYP3A5 described in the first aspect of the present invention in the preparation of a drug for sensitizing glioblastoma patients to TMZ.
[0043] Furthermore, the reagent for detecting the expression level of the biomarker CYP3A5 in the sample includes a reagent for detecting the expression level of the biomarker CYP3A5 mRNA in the sample, and / or a reagent for detecting the expression level of the protein and / or polypeptide encoded by the biomarker CYP3A5 in the sample.
[0044] Furthermore, the reagent for detecting the expression level of the biomarker CYP3A5 mRNA in the sample includes a probe that specifically recognizes the biomarker CYP3A5, and / or a primer that specifically amplifies the biomarker CYP3A5.
[0045] Furthermore, the reagent for detecting the expression level of the protein and / or polypeptide encoded by the biomarker CYP3A5 in the sample includes an antibody, and / or an antibody fragment, and / or an affinity protein that specifically binds to the biomarker CYP3A5.
[0046] Furthermore, the sample includes tissue and body fluid.
[0047] Furthermore, the products include chips, test kits, test strips, and microarrays.
[0048] In certain embodiments, determination of "protein expression level", "gene expression" or "gene expression level" as used herein includes but is not limited to determination of corresponding RNA, protein or peptide levels (or a combination thereof). The present invention is not limited to specific methods and reagents for determining protein, peptide or RNA levels, all of which are well known in the art.
[0049] In the present invention, reagents that can be used to detect the expression level of CYP3A5 are well known in the art. Such reagents suitable for the present invention can be purchased commercially or conventionally prepared by methods well known to those skilled in the art.
[0050] In the present invention, a microarray refers to a solid support with a flat surface having an array of nucleic acids, each member of the array comprising identical copies of oligonucleotides or polynucleotides fixed to spatially defined regions or sites that do not overlap with regions or sites of other members of the array; that is, the regions or sites are spatially discrete. In addition, spatially defined hybridization sites may be "addressable" in that their positions and the identities of their immobilized oligonucleotides are known or predetermined (e.g., known or predetermined prior to their use). Typically, the oligonucleotides or polynucleotides are single-stranded and are covalently linked to the solid support, typically by the 5'-end or the 3'-end. The density of nucleic acids containing non-overlapping regions in a microarray is typically greater than 100 / cm 2 , more preferably greater than 1000 / cm 2 .
[0051] In the present invention, the terms "subject", "patient" and "individual" are used interchangeably herein and refer to warm-blooded animals, such as mammals. The term includes, but is not limited to, livestock, rodents (such as rats and mice), primates and humans. Preferably, the term refers to humans.
[0052] A fifth aspect of the present invention provides a method for regulating the expression level of CYP3A5 in glioblastoma cells.
[0053] Furthermore, the method comprises the following step: introducing a substance that inhibits STAT3 expression or activity, or promotes STAT3 phosphorylation, into glioblastoma.
[0054] Furthermore, when a substance that inhibits STAT3 expression or activity is introduced into glioblastoma, the expression level of CYP3A5 decreases; when a substance that promotes STAT3 phosphorylation is introduced into glioblastoma, the expression level of CYP3A5 increases.
[0055] In the present invention, the term "STAT3" refers to a gene located on chromosome 17, and the protein encoded by it is a member of the STAT protein family, which plays an important role in various biological processes such as cell proliferation, survival, differentiation, angiogenesis, and immune regulation. The STAT3 protein is composed of about 770 amino acids and has 6 functional conserved domains, namely, the amino-terminal domain, the coiled-coil domain, the DNA binding domain, the linker domain, the SRC homology 2 domain, and the carboxyl-terminal transactivation domain.
[0056] In a specific embodiment of the present invention, we found that in glioblastoma, STAT3 can regulate the expression of CYP3A5. Specifically, after knocking out STAT3, the expression level of CYP3A5 decreased, while after activating STAT3 or promoting STAT3 phosphorylation, the expression level of CYP3A5 increased.
[0057] A sixth aspect of the present invention provides a method for inhibiting the proliferation of glioblastoma cells.
[0058] Furthermore, the method comprises the following steps: introducing the inhibitor of the biomarker CYP3A5 described in the first aspect of the present invention into glioblastoma cells, and optionally, the inhibitor comprises a substance that inhibits the expression or activity of STAT3.
[0059] In the context of the present invention, the terms "comprises", "comprising", "having", "containing" or "involving" are used to mean inclusive or open-ended, and do not exclude other unlisted elements or method steps. The term "consisting of" is considered to be a preferred embodiment of the term "comprising". If a group is defined herein as comprising at least a certain number of embodiments, this should also be understood to disclose a group that preferably consists only of these embodiments.
[0060] Advantages and beneficial effects of the present invention:
[0061] The biomarker CYP3A5 provided by the present invention is a potential therapeutic target for glioblastoma. It plays an important role in the diagnosis, prognosis, treatment and chemotherapy resistance of glioblastoma, can help clinicians effectively treat glioma patients, and has important clinical application value. BRIEF DESCRIPTION OF THE DRAWINGS
[0062] The embodiments of the present invention are described in detail below with reference to the accompanying drawings, wherein:
[0063] Figure 1 This is a correlation diagram between CYP3A5 and GBM progression and stemness; Figure 1 A in the figure is a flowchart describing the strategy for identifying CYP3A5 targets; Figure 1B is a representative immunohistochemical image and quantitative graph of CYP3A5 expression in low-grade glioma (LGG, n = 59), high-grade glioma (HGG, n = 121) and three normal brain tissues detected by microarray; Figure 1 C is a box plot of CYP3A5 expression levels in individual samples of the TCGA glioma cohort according to WHO grade; Figure 1 DF is the Kaplan–Meier curve of GBM samples stratified by the optimal cutoff value of CYP3A5 expression level in different data sets; Figure 1 G is the principal component analysis (PCA) plot of single-cell RNA sequencing data of 65,655 GSCs and 14,207 GBM cells; Figure 1 H is the expression of CYP3A5, CD133, SOX2 and GFAP in GSCs and their matched adherent DGCs analyzed by Western blot; Figure 1 I is the immunofluorescence analysis of CYP3A5, SOX2, and CD133 in five randomly selected microscopic fields of six GBM samples;
[0064] Figure 2 The results of in vivo and in vitro experiments verifying the inhibitory effect of CYP3A5 knockout on glioma; Figure 2 A is the result graph of CYP3A5 expression level in glioma cells after CYP3A5 knockout; Figure 2 B is the result of Western blotting to detect the protein levels of SOX2 and CD133 in GSCs after CYP3A5 knockout; Figure 2 C is a representative image and quantitative graph of neurospheres in GSCs with or without CYP3A5 knockout; Figure 2 D is a graph showing the frequency of neurosphere formation after CYP3A5 knockout detected by in vitro limiting dilution assay (ELDAs); Figure 2 E is a graph showing the growth of GSCs after CYP3A5 knockout as a cell viability assay; Figure 2 F is a representative image of wild-type and CYP3A5-KO GSCs and a quantitative graph of the proliferation index (EdU+ cells / Hoechst cells); Figure 2 G is the immunoblotting results of CYP3A5, SOX2 and CD133 in GSCs with or without CYP3A5 overexpression; Figure 2 H is a graph showing the neurosphere-forming ability of GSCs after CYP3A5 overexpression; Figure 2 IJ are representative images and quantitative graphs of bioluminescence intensity of U87MGGSCs implanted into nude mice brain with or without CYP3A5 KO; Figure 2 K is the Kaplan-Meier survival curve of nude mice; Figure 2L is a representative image of H&E staining of tumor sections; Figure 2 M is a representative image and quantitative graph of Ki-67 and SOX2 immunohistochemical staining;
[0065] Figure 3 CYP3A5 makes tumors sensitive to TMZ; Figure 3 A is a box plot of the ROC plotter dataset of CYP3A5 mRNA expression in GBM patients after TMZ treatment (responders n=55, non-responders n=35); Figure 3 B is the Kaplan-Meier curve of TMZ-treated TCGAGBM samples stratified by the optimal cutoff value of CYP3A5 expression level; Figure 3 C and D are graphs showing the results of cell viability assays in GSCs with or without CYP3A5KO with increasing TMZ concentrations; Figure 3 E is the immunoblot of PARP and γH2AX in control and CYP3A5 KO GSCs treated with DMSO or TMZ; Figure 3 FH is the result of cell viability assay in GSCs with or without CYP3A5 overexpression, with increasing TMZ concentration; Figure 3 I is a graph showing immunoblotting of γH2AX in control and CYP3A5-overexpressing GSCs treated with DMSO or TMZ;
[0066] Figure 4 This is a diagram of the therapeutic effect of the CYP3A5 inhibitor Cobicistat (Cobi) combined with TMZ on glioma; Figure 4 A is the structural diagram of Cobicistat (Cobi); Figure 4 B is the NAD+ / NADH result of GSCs treated with the indicated concentrations of Cobi; Figure 4 C is a graph showing changes in oxygen consumption rate (OCR) of GSCs treated with the indicated concentrations of Cobi; Figure 4 D is the effect of Cobi on cell viability; Figure 4 E is an immunoblot analysis of PARP, γH2AX, CD133, and PUMA in GSCs treated with Cobi and TMZ;
[0067] Figure 4 F is the calculation and visualization diagram of the synergistic effect score of the combination of Cobi and TMZ; Figure 4 GH is a representative image and quantitative graph of cell apoptosis detected by flow cytometry; Figure 4IJ are representative images and quantitative graphs of bioluminescence intensity of U87MG GSCs in nude mice treated with DMSO, TMZ (5 mg / kg), Cobi (10 mg / kg) or TMZ (5 mg / kg) + Cobi (10 mg / kg) by oral gavage; Figure 4 K is the Kaplan-Meier survival curve of nude mice; Figure 4 L is a representative image of H&E staining of tumor sections; Figure 4 M is a representative image and quantitative analysis of Ki-67 immunofluorescence staining; Figure 4 N is the change diagram of AST and ALT activities in mice of the experimental group; Figure 4 O is the concentration of Cobi (10 mg / kg, oral gavage) in the plasma, brain and xenografts of tumor-bearing mice detected by liquid chromatography-tandem mass spectrometry (LC-MS);
[0068] Figure 5 This is a diagram showing the effect of STAT3 on the transcription level of CYP3A5 in GSCs; Figure 5 A is a diagram showing the screening results of potential transcription factors of CYP3A5; Figure 5 B is the expression level of CYP3A5 mRNA after knocking out STAT3 by qPCR analysis; Figure 5 C is the result of immunoblotting detection of total STAT3, phosphorylated STAT3 (Try 705, p-STAT3) and CYP3A5 after STAT3 knockout; Figure 5 D is the map of STAT3 binding sites in the CYP3A5 promoter region predicted using JASPAR data; Figure 5 E is a graph showing the enrichment of STAT3 binding on the input by ChIP-qPCR using two primers in the CYP3A5 promoter region and one negative control primer; Figure 5 F is the immunoblot of GSCs treated with the indicated concentrations of epidermal growth factor (EGF);
[0069] Figure 5 G is the immunoblot of GSCs treated with EGF at different time periods; Figure 5 H is the immunoblot image of GSCs with or without overexpression of EGFRVIII; Figure 5 I is the immunoblot of GSCs treated with TMZ at different time periods; Figure 5 J is a schematic diagram of the hypothetical signal cascade. DETAILED DESCRIPTION
[0070] In the present invention, the experiments were repeated at least 3 times, and all statistical analyses were performed using R (version 4.1.3) and GraphPad Prism (version 9.5.0). Two-tailed unpaired Student's t test and Wilcoxon test were used to compare the differences in continuous variables between the two groups. Multiple groups of data were tested using one-way analysis of variance. Survival analysis used Log-rank statistical analysis of Kaplan-Meier survival curves. Unless otherwise stated, all data are expressed as mean ± standard deviation. Differences were considered significant when p≤0.05.
[0071] The present invention is further described below in conjunction with specific embodiments, which are only used to explain the present invention and cannot be understood as limiting the present invention. It can be understood by those skilled in the art that various changes, modifications, substitutions and variations can be made to these embodiments without departing from the principles and purpose of the present invention, and the scope of the present invention is defined by the claims and their equivalents. The experimental methods used in the following embodiments are conventional methods unless otherwise specified; the reagents, biological materials, etc. used in the following embodiments, unless otherwise specified, can all be obtained from commercial sources.
[0072] Example 1 Detection of the correlation between CYP3A5 and GBM progression and stemness
[0073] 1. Experimental methods
[0074] 1) Computer data acquisition
[0075] The Cancer Genome Atlas (TCGA) data were obtained using the TCGAbiolinks R package. In addition, this study also included glioma patient cohorts from GSE (http: / / www.ncbi.nlm.nih.gov / geo / ), including GSE68848, GSE13041, GSE16011, and the Chinese Glioma Genome Atlas (CGGA, http: / / www.cgga.org.cn / ).
[0076] Single-cell sequencing data of glioblastoma cells were downloaded from the Broad Institute Single Cell Portal.
[0077] 2) Human glioma specimens
[0078] Informed consent was obtained from patients undergoing glioma resection in the Department of Neurosurgery, First Medical Center, PLA General Hospital for the use of tumor and adjacent non-tumor tissues in this study. The experimental protocol was approved by the Ethics Committee of the First Medical Center, PLA General Hospital (Approved by the Ethics Committee of the First Medical Center, PLA General Hospital; No. S2018-089). Tissue microarray slides containing 122 high-grade and 58 low-grade glioma samples were operated by Shanghai Well Biotechnology Co., Ltd.
[0079] 3) Cell culture and reagents
[0080] As described previously, patient-derived GSCs donated by Beijing Tiantan Hospital were used in this study. U87-MG, LN229, and U251 were purchased from the American Type Culture Collection (ATCC). Patient-derived GSCs, U87MG, LN229, and U251 cultures were cultured as neurospheres in serum-free medium consisting of DMEM / F12, B27 lacking vitamin A (Invitrogen), 2 μg / mL heparin (STEMCELL), 20 ng / mL EGF (R&D), and 20 ng / mL bFGF (R&D). Spheres were isolated using Accutase (Sigma) for in vitro experiments. GSCs were cultured in DMEM / F12 containing 10% fetal bovine serum for 7 days and differentiated into DGCs. The authenticity of all cultures was monitored by short tandem repeats (STRs), and mycoplasma testing was routinely performed. Nicotinamide mononucleotide, cobicistat, resveratrol, and WP1066 were purchased from MCE. Temozolomide was purchased from Sigma Aldrich.
[0081] 4) Western Blot
[0082] Proteins were extracted from cells using radioimmunoprecipitation (RIPA) protein lysis buffer, separated by SDS-PAGE, and then transferred to polyvinylidene fluoride (PVDF) membranes. After incubation with primary antibodies overnight at 4°C, the membranes were incubated with enzyme-conjugated secondary antibodies.
[0083] 5) Immunoprecipitation
[0084] Equal amounts of 500ul of cell lysate were incubated with primary antibody at 4°C overnight with rotation. The next day, pre-washed magnetic beads were added to the immune complex and rotated at room temperature for 30 minutes. The magnetic separation rack was washed three times, boiled in loading buffer at 100°C for 10 minutes, and then analyzed by western blot.
[0085] 6) Immunofluorescence staining
[0086] Cultures or tissue sections were fixed with 4% formaldehyde for 20 minutes at room temperature and then washed with PBS. Subsequently, they were permeabilized with 0.3% TritonX-100 for 5 minutes at room temperature. Then they were incubated with primary antibodies overnight at 4°C and then with corresponding secondary antibodies for 1 hour at room temperature. Finally, the nuclei were counterstained with DAPI.
[0087] For TSA staining, after antigen retrieval, samples were blocked with 3% BSA for 30 minutes at room temperature, then reacted with primary antibodies overnight at 4°C, and then reacted with appropriate secondary antibodies for 1 hour at room temperature. Then, incubated with tyramide signal amplification (TSA) plus fluorescein kit for 10 minutes at room temperature. Antibody elution was performed by heating the slides in a microwave. Then, the next primary antibody was added according to the above steps. Cell nuclei were counterstained with DAPI. All images were observed by FV-1000 laser scanning confocal microscope (Olympus Corporation, Japan).
[0088] 2. Experimental results
[0089] We attempted to identify druggable target genes that may have potential therapeutic implications for glioma patients. Figure 1 A. 2249 drug target genes were screened from the Drug Repurposing Center, and four key candidate genes were found - CKMT2, CYP3A5, CLCN2 and PIEZO1. Among the four candidate genes, CYP3A5 performed well in distinguishing prognostic outcomes using a single covariate Cox proportional hazard model, and the perturbation effect analysis of target loss in the Cmap database showed that CYP3A5 had the lowest normalized connectivity score.
[0090] We then evaluated the relationship between CYP3A5 expression status and clinical and molecular characteristics of glioma. Figure 2 As shown in B and C, the expression of CYP3A5 is significantly increased in glioma patients and increases with the WHO grade of glioma. It is higher in the highly invasive classical subtype and mesenchymal subtype. In addition, it was found from various databases that there is a significant correlation between increased CYP3A5 expression and poor prognosis in GBM patients ( Figure 1 DF), patients with high CYP3A5 expression had a shorter survival time.
[0091] Next, we examined whether CYP3A5 is involved in the occurrence of GBM. Through the analysis of large-scale transcriptomic data of gliomas in the TCGA and CGGA cohorts and RT-qPCR analysis of 28 frozen glioma samples in our cohort, we found that CYP3A5 expression levels were positively correlated with most stem cell-related genes. In addition, principal component analysis of single-cell RNA sequencing data of 65,655 GSCs and 14,207 GBM cells revealed that areas with high CYP3A5 expression also contained cells that significantly expressed cancer stem cell markers, such as PROM1, NOTCH1, and BMI1 ( Figure 1 G). In addition, the transcription and translation levels of CYP3A5 were higher in glioblastoma stem-like cells (GSCs) maintained under serum-free conditions than in differentiated glioblastoma adherent cells (DGCs) cultured in serum-supplemented medium ( Figure 1 H). In addition, co-immunofluorescence (IF) staining of human GBM surgical specimens revealed that CYP3A5 was preferentially expressed in cancer cells expressing the GSC markers SOX2 and CD133 ( Figure 1 I).
[0092] Collectively, these results indicate that CYP3A5 is associated with the progression and stemness of GBM, indicating that CYP3A5 is highly expressed in glioma patients and is associated with the poor prognosis of GBM patients, suggesting that CYP3A5 is a potential therapeutic target for GBM.
[0093] Example 2 The therapeutic effect of CYP3A5 on glioma patients
[0094] 1. Experimental methods
[0095] 1) Xenotransplantation studies
[0096] Four-week-old BALB / C female nude mice were purchased from Beijing Vital River Experimental Animal Technology Co., Ltd. and housed in the pathogen-free barrier animal facility of Tianjin Institute of Neurology, Tianjin Medical University General Hospital. All mouse experiments were in accordance with the Animal Ethics and Welfare Committee of Tianjin Medical University (No: IRB2022-DWFL-069). For intracranial tumor xenografts, luciferase lentivirus-infected neurospheres were stereotactically implanted into the right frontal lobe of mice at a depth of 3 mm. Tumor growth was monitored using the IVIS Lumina imaging station. Mice in each group were killed on the same day after transplantation, and tumor size was compared using H&E staining. The brain was then collected, fixed in 4% paraformaldehyde, and subsequently embedded in paraffin and sectioned. For survival analysis, animals were maintained until neurological signs were observed.
[0097] 2) Construction of knockout, knockdown and overexpression cells
[0098] To stably express cas9, we first infected glioma cells with leti-FLAG-Cas9-Bsdr lentivirus and then selected them with 10 μg / ml Blasticidin. Then, CYP3A5 KO cells were constructed by transducing the let-sgRNA-puro lentiviral vector into cells expressing cas9. Stable cell lines were transfected with 2 μg / ml puromycin, and the CRISPR-KO efficiency was detected by western blot. siRNAs targeting human STAT3 were transduced into cells using Lipofectamine-3000 (Invitrogen). For CYP3A5 overexpression, CYP3A5 overexpression plasmids were transfected with Lipofectamine-3000. For EGFRvIII overexpression, cells were transduced with EGFR-vIII lentiviral particles and selected with 2 μg / mL puromycin. Gene knockdown and overexpression efficiency were detected by qPT-PCR and western blot.
[0099] 3) In vitro limiting dilution test and tumor sphere formation test
[0100] Glioma sphere cells were seeded in 96-well plates at densities of 1, 5, 10, 20, 40, 80, and 160 cells per well, and repeated 10 times. After 7 days, cells without spheres (diameter ≥ 50 μm) were counted and analyzed by the ELDA website (https: / / bioinf.wehi.edu.au / software / elda / ). Tumor sphere formation experiment 1000 glioma sphere cells per well were implanted in 96-well plates and cultured for 7 days. Neurospheres ≥ 50 μm in each well were counted.
[0101] 4) Cell viability assay
[0102] Cells were seeded in 96-well plates at 2 or 5 × 10 3 Cells were used to observe cell proliferation and drug toxicity, respectively. Cell viability was detected using CCK8 assay (Dojindo) according to the manufacturer's instructions. Cell proliferation data were normalized to day 1.
[0103] 5) EdU incorporation assay
[0104] EdU incorporation experiments were performed using the Click-iT EdU imaging kit (Thermo Fisher) following the manufacturer's protocol. Briefly, GSCs were incubated in 10 μM EdU for 2 h. The cells were then fixed and permeabilized before Click-iT reaction and Hoechst 33342 staining. The proliferation index was calculated by a blinded investigator by dividing the number of EdU-labeled cells by the number of Hoechst-labeled cells.
[0105] 2. Experimental results
[0106] To further explore the role of CYP3A5 in GSCs maintenance, we knocked out or overexpressed CYP3A5 in GSCs. We used two non-overlapping sgRNAs to target KO of CYP3A5, resulting in effective loss of endogenous CYP3A5 expression. After loss, we observed a significant decrease in the expression levels of GSCs markers CD133 and SOX2 ( Figure 2 AB). At the same time, inhibition of GSC self-renewal was also observed in CYP3A5 KO, which was supported by the results of sphere formation assay and in vitro limiting dilution assay ( Figure 2 CD). In addition, cell viability and EdU incorporation experiments demonstrated that the proliferation capacity of GSCs was attenuated after CYP3A5 KO ( Figure 2 EF). Consistent with this, increased expression of GSC markers CD133 and SOX2 and enhanced GSC self-renewal were also detected after CYP3A5 overexpression ( Figure 2 GH).
[0107] Next, targeted knockout (KO) of CYP3A5 by transducing non-overlapping sgRNAs into Cas9-expressing GSCs suppressed xenograft tumor growth and improved mouse survival, as demonstrated by bioluminescence imaging (BLI) analysis, hematoxylin and eosin (H&E) staining, and survival analysis ( Figure 2 IL). Meanwhile, we found that CYP3A5 KO led to a significant decrease in the number of SOX2 and Ki67 tumor cells in GBM xenografts ( Figure 2 M). In summary, these results indicate that inhibiting CYP3A5 expression can inhibit the proliferation of glioma cells, and also prove that targeting CYP3A5 can play a therapeutic role in glioma patients.
[0108] Example 3 CYP3A5 sensitizes tumors to TMZ
[0109] 1. Experimental methods
[0110] Flow cytometric analysis of cell apoptosis and cell cycle
[0111] According to the manufacturer's instructions, a cell apoptosis assay was performed using 7-AAD and annexin V (Yeasen, Cat#40310ES60). The proportion of apoptotic cells was detected by flow cytometry (BD Biosciences, USA). The cells were collected and stored at 4°C with 70% ethanol for 12 hours. Subsequently, the fixed cells were rinsed with PBS and treated with RNase I. Finally, the cells were stained with PI for 15 minutes, and then cell cycle analysis was performed using a BD flow cytometer.
[0112] 2. Experimental results
[0113] In GBM patients treated with TMZ, higher levels of CYP3A5 ( Figure 3 A). In addition, in GBM patients receiving TMZ treatment, patients with low CYP3A5 expression had a better prognosis than those with high CYP3A5 expression ( Figure 3 B). Next, we tested whether CYP3A5 promoted the resistance of GSCs to TMZ in vitro. Cell viability experiments with increasing doses of TMZ showed that CYP3A5 KO sensitized GSCs to TMZ ( Figure 3 CD). In addition, CYP3A5KO enhanced TMZ-induced DNA damage and apoptosis, as indicated by increased levels of γH2AX and cleaved PARP ( Figure 3 E). Consistently, overexpression of CYP3A5 enhanced the resistance of GSCs to TMZ, as indicated by increased cell viability and decreased γH2AX levels after TMZ treatment ( Figure 3 FI).
[0114] Taken together, these results indicate that CYP3A5 can predict whether glioma patients are sensitive to TMZ and that inhibitors targeting CYP3A5 can enhance the sensitivity of glioma patients to TMZ.
[0115] Example 4 Therapeutic effect of CYP3A5 inhibitor combined with TMZ on glioma
[0116] 1. Experimental methods
[0117] 1) Animal experiment: 4-week-old BALB / C female nude mice were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. and housed in the pathogen-free barrier animal facility of Tianjin Institute of Neurology, Tianjin Medical University General Hospital. For combined treatment, 5 mg / kg TMZ (Sigma) and 10 mg / kg Cobicistat (MCE) were administered orally at the specified frequency.
[0118] 2) Collaborative computing method
[0119] The synergy of the combination was evaluated using the SynergyFinder web interface. The synergy score was calculated using the HSA model, and a score greater than 10 indicated the presence of a synergistic interaction.
[0120] 3) NAD + Determination of NADH level
[0121] WST-8 based NAD was used according to the manufacturer's instructions. +The intracellular NAD+ / NADH ratio was assessed using the NADH / NADH assay kit (Beyotime). Briefly, 1×10 6 Cells were lysed in 200 μl of chilled lysis buffer and then centrifuged at 12,000 g for 10 min at 4 °C. To measure NADH, a portion of the supernatant was incubated at 60 °C for 30 min to selectively degrade NAD + Subsequently, NAD was measured using an ELISA reader at 450 nm. + / NADH ratio.
[0122] 4) LC-MS analysis
[0123] Tumor-bearing mice were gavaged with cobicistat (10 mg / kg) buffer solution. Plasma, brain, and xenograft tissues were collected before (0 hour) and 0.5, 1, 4, 8, and 12 hours after administration and analyzed using a Waters UPLC system. The cobicistat concentration of the sample was calculated using an internal standard curve and sample dilution factor, and its level was determined by measuring the area under the curve and the maximum concentration.
[0124] 5) Hippocampal extracellular flux assay
[0125] Oxygen consumption rate (OCR) was measured using an XFe24 extracellular flux analyzer (Agilent) according to the manufacturer's instructions. Briefly, cells were plated onto Seahorse Bioscience plates in Seahorse XF RPMI culture buffer. Mitochondrial function was then assessed by sequential injections of 2 μM oligomycin, 2 μM FCCP, and 0.5 μM rotenone / antimycin A. OCR readings were normalized to cell number.
[0126] 2. Experimental results
[0127] To pharmacologically inhibit CYP3A5, cobicistat (Cobi) is a potent and selective inhibitor of human CYP3A ( Figure 4 A) Cobi significantly down-regulates NAD in a dose-dependent manner in GSCs + / NADH ratio( Figure 4 B). In addition, a decrease in OCR was also observed after Cobi treatment of GSCs in a dose-dependent manner ( Figure 4 C) These results suggest that Cobi can replicate CYP3A5 deficiency in NAD + Furthermore, Cobi showed preferential cytotoxic effects on GSCs compared with matched DGCs ( Figure 4D). Next, we tested the synergistic effect of TMZ and Cobi combined on GSCs. As expected, Cobi enhanced TMZ-induced apoptosis and DNA damage, as evidenced by cleaved PARP and increased γH2AX levels ( Figure 4 E). Notably, Cobi reversed TMZ-induced upregulation of the stemness marker CD133 and enhanced TMZ-induced expression of the mitochondrial outer membrane permeability protein PUMA ( Figure 4 E). Further drug combination dose-response matrix data analysis and flow cytometry apoptosis experiments showed that Cobi and TMZ had a synergistic effect ( Figure 4 FH).
[0128] Next, we determined the in vivo efficacy of Cobi combined with TMZ in the treatment of GBM. Notably, in an established orthotopic GBM xenograft model, the combination of Cobi and TMZ showed superior efficacy in inhibiting tumor growth and prolonging overall survival compared with Cobi or TMZ alone ( Figure 4 IL). Immunofluorescence staining of tumor sections showed that the expression of proliferation marker Ki67 was significantly decreased after combined treatment ( Figure 4 M). In addition, neither single treatment nor the combination of Cobi and TMZ induced any observable signs of toxicity based on assessment of serum aspartate aminotransferase and alanine aminotransferase levels and histological staining of the liver, kidney, or heart ( Figure 4 N). Drug distribution analysis showed that after entering the plasma, the concentration of Cobi in tumor tissue was higher than that in non-tumor brain tissue ( Figure 4 O). Taken together, these results suggest that Cobi can be delivered into brain tumors to synergize with TMZ to inhibit GBM growth.
[0129] Example 5 STAT3 regulates CYP3A5 transcription levels in GSCs
[0130] 1. Experimental methods
[0131] 1) RNA isolation and real-time quantitative PCR
[0132] Total RNA was extracted with TRIzol reagent and reverse transcribed. qRT-PCR was then performed using SYBR Green mixture on the QuantStudio 3 Real-Time PCR System (Thermo Scientific). GAPDH was used for normalization.
[0133] 2) Chromatin immunoprecipitation (ChIP) assay
[0134] use ChIP assays were performed using Enzymatic Chromatin IP Kit (#9003, CST) according to the manufacturer’s protocol. Briefly, 1 × 10 7 Cells were cross-linked with 1% formaldehyde for 10 minutes at room temperature and then quenched with glycine. Subsequently, cells were collected, chromatin was digested with micrococcal nuclease, and then sonicated to obtain DNA fragments of 150-900bp. For immunoprecipitation, 5ul of STAT3 antibody (#9139, CST) was added to the diluted chromatin, incubated with rotation at 4°C overnight, and then magnetic beads were added at 4°C for 2h. After eluting chromatin from the magnetic beads and reversing the cross-links, the chip DNA samples were purified and analyzed by qRT-PCR.
[0135] 2. Experimental results
[0136] To explore the mechanism of elevated CYP3A5 expression in GSCs, we first queried the KockTF dataset and identified 23 potential transcription factors (TFs) for CYP3A5 ( Figure 5 A). We analyzed these transcription factors (TFs) using the University of California Santa Cruz (UCSC) genome browser and found that two TFs (ESRRA, STAT3) had JASPAR binding scores exceeding 400 ( Figure 5 A). We next tested whether STAT3 promotes CYP3A5 transcription. Notably, knockdown of STAT3 using two independent, non-overlapping siRNAs resulted in a significant decrease in CYP3A5 mRNA and protein expression levels ( Figure 5 BC). Further ChIP-qPCR analysis showed that STAT3 had an enhanced binding affinity with GSCs in the CYP3A5 promoter region compared with the negative control site ( Figure 5 DE).
[0137] Since EGFR signaling and TMZ have been reported to increase p-STAT3 levels, we hypothesized that EGFR pathway or TMZ-induced STAT3 activation could potentially upregulate CYP3A5 expression, partially explaining CYP3A5-mediated stemness and chemoresistance. After overnight starvation of GSCs, epidermal growth factor (EGF) treatment significantly increased p-STAT3 and CYP3A5 levels in a time- and dose-dependent manner, accompanied by activated EGFR signaling ( Figure 5 FG). EGFR signaling can be activated by EGFR variant III (EGFRvIII) in a ligand-independent manner. As expected, overexpression of EGFRvIII in GSCs replicated the effects observed with EGF treatment ( Figure 5H). In addition, a period of TMZ treatment also significantly increased the levels of p-STAT3 and CYP3A5 ( Figure 5 I). Taken together, these results suggest that EGFR signaling and TMZ can activate p-STAT3, thereby increasing the expression of CYP3A5 in GSCs ( Figure 5 J).
[0138] The description of the above embodiments is only used to understand the method and core idea of the present invention. It should be pointed out that, for those skilled in the art, several improvements and modifications can be made to the present invention without departing from the principle of the present invention, and these improvements and modifications will also fall within the scope of protection of the claims of the present invention.
Claims
1. A glioblastoma-related biomarker, It is characterized in that The biomarker is CYP3A5; Optionally, the biomarker can be used for diagnosis, prognosis, prevention and / or treatment of glioblastoma; Optionally, the expression level of the biomarker CYP3A5 is significantly increased in glioblastoma.
2. A product for early diagnosis or prediction of the prognosis of glioblastoma, It is characterized in that The product comprises a reagent for detecting the expression level of the biomarker CYP3A5 according to claim 1.
3. The product according to claim 2, It is characterized in that The products include chips, test kits, test strips, and high-throughput sequencing platforms; Preferably, the reagent for detecting the expression level of the biomarker CYP3A5 in the sample includes a reagent for detecting the expression level of the biomarker CYP3A5 mRNA in the sample, and / or a reagent for detecting the expression level of the protein and / or polypeptide encoded by the biomarker CYP3A5 in the sample; Preferably, the reagent for detecting the expression level of the biomarker CYP3A5 mRNA in the sample comprises a probe that specifically recognizes the biomarker CYP3A5, and / or a primer that specifically amplifies the biomarker CYP3A5; Preferably, the reagent for detecting the expression level of the protein and / or polypeptide encoded by the biomarker CYP3A5 in the sample comprises an antibody, and / or an antibody fragment, and / or an affinity protein that specifically binds to the biomarker CYP3A5.
4. A pharmaceutical composition for treating glioblastoma, It is characterized in that The pharmaceutical composition comprises an inhibitor targeting the biomarker CYP3A5 according to claim 1.
5. The pharmaceutical composition according to claim 4, It is characterized in that The inhibitor refers to any substance that can reduce the expression of nucleic acid encoding CYP3A5, reduce the level of CYP3A5 protein, or inhibit the activity of CYP3A5, preferably a substance that reduces the activity of CYP3A5 protein, reduces the stability of CYP3A5 gene or protein, downregulates the expression of CYP3A5, reduces the effective action time of CYP3A5 protein, or inhibits the transcription and translation of CYP3A5; Preferably, the inhibitor comprises Cobicistat; Preferably, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier and / or excipient; Preferably, the pharmaceutical composition is temozolomide (TMZ) and Cobicistat; More preferably, the ratio of Cobicistat to TMZ is 2:
1.
6. An application, It is characterized in that The application includes any of the following: 1) Use of a reagent for detecting the expression level of the biomarker CYP3A5 described in claim 1 in a sample in the preparation of a product for early diagnosis or prognosis of glioblastoma; 2) Use of the pharmaceutical composition according to any one of claims 4 to 5 in the preparation of a product for preventing and / or treating glioblastoma; 3) Use of a reagent for detecting the expression level of the biomarker CYP3A5 according to claim 1 in a sample in the preparation of a product for evaluating and / or predicting the sensitivity of glioma patients to TMZ, preferably, in non-responsive glioblastoma patients receiving TMZ treatment, the CYP3A5 expression level is significantly higher than that in responsive patients receiving TMZ treatment; 4) Use of an inhibitor targeting the biomarker CYP3A5 according to claim 1 in the preparation of a drug for sensitizing glioblastoma patients to TMZ.
7. The use according to claim 6, wherein the reagent for detecting the expression level of the biomarker CYP3A5 in the sample comprises a reagent for detecting the expression level of the biomarker CYP3A5 mRNA in the sample, and / or a reagent for detecting the expression level of the protein and / or polypeptide encoded by the biomarker CYP3A5 in the sample; Preferably, the reagent for detecting the expression level of the biomarker CYP3A5 mRNA in the sample comprises a probe that specifically recognizes the biomarker CYP3A5, and / or a primer that specifically amplifies the biomarker CYP3A5; Preferably, the reagent for detecting the expression level of the protein and / or polypeptide encoded by the biomarker CYP3A5 in the sample comprises an antibody, and / or an antibody fragment, and / or an affinity protein that specifically binds to the biomarker CYP3A5; Preferably, the sample includes tissue or body fluid; Preferably, the product comprises a chip, a kit, or a microarray.
8. A method for regulating the expression level of CYP3A5 in glioblastoma cells, It is characterized in that The method comprises the following steps: introducing a substance that inhibits STAT3 expression or activity, or promotes STAT3 phosphorylation, into glioblastoma.
9. The method according to claim 8, It is characterized in that When substances that inhibit STAT3 expression or activity are introduced into glioblastoma, CYP3A5 expression levels decrease; when substances that promote STAT3 phosphorylation are introduced into glioblastoma, CYP3A5 expression levels increase.
10. A method for inhibiting the proliferation of glioblastoma cells, It is characterized in that The method comprises the following steps: introducing the inhibitor of the biomarker CYP3A5 according to claim 1 into glioblastoma cells, and optionally, the inhibitor comprises a substance that inhibits the expression or activity of STAT3.
Citation Information
Patent Citations
Application of NUP98 gene as glioma stem cell specific molecular marker and glioblastoma treatment and prognosis target
CN114381522A
Novel methods for sub-typing and treating cancer
US20170260593A1
